A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy

PURPOSE: Effective second‐line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase inhibitor. Such inhibitors increase sensitivity to fluorouracil, the active form of S‐1. In the phase I study, addition of resminostat to S‐1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Makoto, Morizane, Chigusa, Furukawa, Masayuki, Sakai, Daisuke, Komatsu, Yoshito, Nakai, Yousuke, Tsuda, Masahiro, Ozaka, Masato, Mizuno, Nobumasa, Muto, Manabu, Fukutomi, Akira, Ikeda, Masafumi, Tsuji, Akihito, Katanuma, Akio, Moriwaki, Toshikazu, Kajiwara, Takeshi, Ishii, Hiroshi, Negoro, Yuji, Shimizu, Satoshi, Nemoto, Noriko, Kobayashi, Shingo, Makino, Keigo, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957161/
https://www.ncbi.nlm.nih.gov/pubmed/33635605
http://dx.doi.org/10.1002/cam4.3813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957161/
https://www.ncbi.nlm.nih.gov/pubmed/33635605
http://dx.doi.org/10.1002/cam4.3813

Ejemplares similares